Precise glioma targeting of and penetration by aptamer and peptide dual-functioned nanoparticles

Biomaterials

Volumn 33, Issue 20, 2012, Pages 5115-5123

  Gao, Huile ^a   Qian, Jun ^a   Cao, Shijie ^a   Yang, Zhi ^a   Pang, Zhiqing ^a   Pan, Shuaiqi ^a   Fan, Li ^a   Xi, Zhangjie ^a   Jiang, Xinguo ^a   Zhang, Qizhi ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Brain glioma; Cascade targeting strategy; Glioma bearing survival; Glioma penetration

Indexed keywords

ANTITUMOR DRUGS; APTAMERS; BLOOD-BRAIN BARRIER; BRAIN CANCER; BRAIN TISSUE; CANCER CELLS; DELIVERY SYSTEMS; FLUORESCENT IMAGES; GLIOMA BEARING SURVIVAL; GLIOMA PENETRATION; IN-VITRO; IN-VIVO IMAGING; SIDE EFFECT; TARGETED DELIVERY; TUMOR CELLS; TUMOR SPHEROID;

DRUG INTERACTIONS; ENDOTHELIAL CELLS; MONOLAYERS; NANOPARTICLES; PEPTIDES;

TUMORS;

APTAMER; AS1411; NANOPARTICLE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD BRAIN BARRIER; CANCER CELL; ENDOTHELIUM CELL; GLIOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; APTAMERS, NUCLEOTIDE; BRAIN NEOPLASMS; CELL LINE; DRUG DELIVERY SYSTEMS; GLIOMA; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MICE; MICE, INBRED BALB C; NANOPARTICLES; PEPTIDES;

EID: 84860387204     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2012.03.058     Document Type: Article

References (43)

1. Siegel R., Ward E., Brawley O., Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011, 61(4):212-236.
2. Hegi M.E., Diserens A.C., Gorlia T., Hamou M.F., de Tribolet N., Weller M., et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005, 352(10):997-1003.
3. Serwer L.P., James C.D. Challenges in drug delivery to tumors of the central nervous system: an overview of pharmacological and surgical considerations. Adv Drug Deliv Rev 2012.
4. Donahue M.J., Blakeley J.O., Zhou J., Pomper M.G., Laterra J., van Zijl P.C. Evaluation of human brain tumor heterogeneity using multiple T1-based MRI signal weighting approaches. Magn Reson Med 2008, 59(2):336-344.
5. Yan H., Wang J., Yi P., Lei H., Zhan C., Xie C., et al. Imaging brain tumor by dendrimer-based optical/paramagnetic nanoprobe across the blood-brain barrier. Chem Commun (Camb) 2011, 47(28):8130-8132.
6. Pardridge W.M. Drug targeting to the brain. Pharm Res 2007, 24(9):1733-1744.
7. Agarwal S., Sane R., Oberoi R., Ohlfest J.R., Elmquist W.F. Delivery of molecularly targeted therapy to malignant glioma, a disease of the whole brain. Expert Rev Mol Med 2011, 13:e17.
8. Wang X., Duan X., Yang G., Zhang X., Deng L., Zheng H., et al. Honokiol crosses BBB and BCSFB and inhibits brain tumor growth in rat 9L intracerebral gliosarcoma model and human U251 xenograft glioma model. PLoS One 2011, 6(4):e18490.
9. Pardridge W.M. Vector-mediated drug delivery to the brain. Adv Drug Deliv Rev 1999, 36(2-3):299-321.
10. Lu W., Sun Q., Wan J., She Z., Jiang X.G. Cationic albumin-conjugated pegylated nanoparticles allow gene delivery into brain tumors via intravenous administration. Cancer Res 2006, 66(24):11878-11887.
11. Gao H., Pan S., Yang Z., Cao S., Chen C., Jiang X., et al. A cascade targeting strategy for brain neuroglial cells employing nanoparticles modified with angiopep-2 peptide and EGFP-EGF1 protein. Biomaterials 2011, 32(33):8669-8675.
12. Li J., Feng L., Fan L., Zha Y., Guo L., Zhang Q., et al. Targeting the brain with PEG-PLGA nanoparticles modified with phage-displayed peptides. Biomaterials 2011, 32(21):4943-4950.
13. Teng Y., Girvan A.C., Casson L.K., Pierce W.J., Qian M., Thomas S.D., et al. AS1411 alters the localization of a complex containing protein arginine methyltransferase 5 and nucleolin. Cancer Res 2007, 67(21):10491-10500.
14. Guo J., Gao X., Su L., Xia H., Gu G., Pang Z., et al. Aptamer-functionalized PEG-PLGA nanoparticles for enhanced anti-glioma drug delivery. Biomaterials 2011, 32(31):8010-8020.
15. Gueritte-Voegelein F., Guenard D., Lavelle F., Le Goff M.T., Mangatal L., Potier P. Relationships between the structure of taxol analogues and their antimitotic activity. J Med Chem 1991, 34(3):992-998.
16. Sampath P., Rhines L.D., DiMeco F., Tyler B.M., Park M.C., Brem H. Interstitial docetaxel (taxotere), carmustine and combined interstitial therapy: a novel treatment for experimental malignant glioma. J Neurooncol 2006, 80(1):9-17.
17. Gao H., Pang Z., Pan S., Cao S., Yang Z., Chen C., et al. Anti-glioma effect and safety of docetaxel-loaded nanoemulsion. Arch Pharm Res 2012, 35(2):333-341.
18. Pang Z., Lu W., Gao H., Hu K., Chen J., Zhang C., et al. Preparation and brain delivery property of biodegradable polymersomes conjugated with OX26. J Control Release 2008, 128(2):120-127.
19. Xu Z., Chen L., Gu W., Gao Y., Lin L., Zhang Z., et al. The performance of docetaxel-loaded solid lipid nanoparticles targeted to hepatocellular carcinoma. Biomaterials 2009, 30(2):226-232.
20. Jones-Bolin S., Zhao H., Hunter K., Klein-Szanto A., Ruggeri B. The effects of the oral, pan-VEGF-R kinase inhibitor CEP-7055 and chemotherapy in orthotopic models of glioblastoma and colon carcinoma in mice. Mol Cancer Ther 2006, 5(7):1744-1753.
21. Hu K., Li J., Shen Y., Lu W., Gao X., Zhang Q., et al. Lactoferrin-conjugated PEG-PLA nanoparticles with improved brain delivery: in vitro and in vivo evaluations. J Control Release 2009, 134(1):55-61.
22. Kobayashi H., Man S., Graham C.H., Kapitain S.J., Teicher B.A., Kerbel R.S. Acquired multicellular-mediated resistance to alkylating agents in cancer. Proc Natl Acad Sci U S A 1993, 90(8):3294-3298.
23. Du J., Lu W.L., Ying X., Liu Y., Du P., Tian W., et al. Dual-targeting topotecan liposomes modified with tamoxifen and wheat germ agglutinin significantly improve drug transport across the blood-brain barrier and survival of brain tumor-bearing animals. Mol Pharm 2009, 6(3):905-917.
24. Zhan C., Gu B., Xie C., Li J., Liu Y., Lu W. Cyclic RGD conjugated poly(ethylene glycol)-co-poly(lactic acid) micelle enhances paclitaxel anti-glioblastoma effect. J Control Release 2010, 143(1):136-142.
25. Kim S.Y., Lee Y.M., Baik D.J., Kang J.S. Toxic characteristics of methoxy poly(ethylene glycol)/poly(epsilon-caprolactone) nanospheres; in vitro and in vivo studies in the normal mice. Biomaterials 2003, 24(1):55-63.
26. Maeda H. Smancs and polymer-conjugated macromolecular drugs: advantages in cancer chemotherapy. Adv Drug Deliv Rev 2001, 46(1-3):169-185.
27. Matsumura Y., Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 1986, 46(12 Pt 1):6387-6392.
28. Torchilin V.P. Passive and active drug targeting: drug delivery to tumors as an example. Handb Exp Pharmacol 2010, 197:3-53.
29. Fang J., Sawa T., Maeda H. Factors and mechanism of "EPR" effect and the enhanced antitumor effects of macromolecular drugs including SMANCS. Adv Exp Med Biol 2003, 519:29-49.
30. Hobbs S.K., Monsky W.L., Yuan F., Roberts W.G., Griffith L., Torchilin V.P., et al. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc Natl Acad Sci U S A 1998, 95(8):4607-4612.
31. Yuan F., Dellian M., Fukumura D., Leunig M., Berk D.A., Torchilin V.P., et al. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res 1995, 55(17):3752-3756.
32. Schlageter K.E., Molnar P., Lapin G.D., Groothuis D.R. Microvessel organization and structure in experimental brain tumors: microvessel populations with distinctive structural and functional properties. Microvasc Res 1999, 58(3):312-328.
33. Brannon-Peppas L., Blanchette J.O. Nanoparticle and targeted systems for cancer therapy. Adv Drug Deliv Rev 2004, 56(11):1649-1659.
34. Madhankumar A.B., Slagle-Webb B., Mintz A., Sheehan J.M., Connor J.R. Interleukin-13 receptor-targeted nanovesicles are a potential therapy for glioblastoma multiforme. Mol Cancer Ther 2006, 5(12):3162-3169.
35. Pang Z., Gao H., Yu Y., Chen J., Guo L., Ren J., et al. Brain delivery and cellular internalization mechanisms for transferrin conjugated biodegradable polymersomes. Int J Pharm 2011, 415(1-2):284-292.
36. Nagothu K.K., Jaszewski R., Moragoda L., Rishi A.K., Finkenauer R., Tobi M., et al. Folic acid mediated attenuation of loss of heterozygosity of DCC tumor suppressor gene in the colonic mucosa of patients with colorectal adenomas. Cancer Detect Prev 2003, 27(4):297-304.
37. Zhou J., Rossi J.J. Cell-specific aptamer-mediated targeted drug delivery. Oligonucleotides 2011, 21(1):1-10.
38. Pasqualini R., Ruoslahti E. Organ targeting in vivo using phage display peptide libraries. Nature 1996, 380(6572):364-366.
39. Yan H., Wang L., Wang J., Weng X., Lei H., Wang X., et al. Two-order targeted brain tumor imaging by using an optical/paramagnetic nanoprobe across the blood brain barrier. ACS Nano 2012, 6(1):410-420.
40. Ying X., Wen H., Lu W.L., Du J., Guo J., Tian W., et al. Dual-targeting daunorubicin liposomes improve the therapeutic efficacy of brain glioma in animals. J Control Release 2010, 141(2):183-192.
41. He H., Li Y., Jia X.R., Du J., Ying X., Lu W.L., et al. PEGylated poly(amidoamine) dendrimer-based dual-targeting carrier for treating brain tumors. Biomaterials 2011, 32(2):478-487.
42. Ren J., Shen S., Wang D., Xi Z., Guo L., Pang Z., et al. The targeted delivery of anticancer drugs to brain glioma by PEGylated oxidized multi-walled carbon nanotubes modified with angiopep-2. Biomaterials 2012, 33(11):3324-3333.
43. Sun X., Pang Z., Ye H., Qiu B., Guo L., Li J., et al. Co-delivery of pEGFP-hTRAIL and paclitaxel to brain glioma mediated by an angiopep-conjugated liposome. Biomaterials 2012, 33(3):916-924.